← Back to Search

Tyrosine Kinase Inhibitor

Pemigatinib for Non-Small Cell Lung Cancer (FIGHT-210 Trial)

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 9 months
Awards & highlights

FIGHT-210 Trial Summary

This trial tests a new cancer drug, to see if it is safe and effective, in people with a certain type of lung cancer who have no other treatment options.

Eligible Conditions
  • Non-Small Cell Lung Cancer

FIGHT-210 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cohort A: Overall Response Rate (ORR)
Secondary outcome measures
Cohort A: Duration of Response (DOR)
Cohort A: Overall Survival (OS)
Cohort A: Progression-Free Survivol (PFS)
+2 more

Side effects data

From 2022 Phase 2 trial • 147 Patients • NCT02924376
59%
Alopecia
56%
Hyperphosphataemia
54%
Diarrhoea
46%
Fatigue
43%
Stomatitis
43%
Constipation
42%
Nausea
42%
Dysgeusia
39%
Dry mouth
35%
Dry eye
34%
Arthralgia
32%
Vomiting
31%
Decreased appetite
28%
Dry skin
26%
Hypophosphataemia
25%
Back pain
24%
Pain in extremity
21%
Palmar-plantar erythrodysaesthesia syndrome
20%
Abdominal pain
19%
Headache
19%
Urinary tract infection
19%
Weight decreased
18%
Dizziness
18%
Epistaxis
15%
Oedema peripheral
15%
Hypercalcaemia
15%
Anaemia
15%
Dehydration
14%
Myalgia
14%
Asthenia
13%
Dyspepsia
12%
Insomnia
12%
Nasal dryness
12%
Gastrooesophageal reflux disease
12%
Pruritus
12%
Onychomadesis
11%
Rash
11%
Blood alkaline phosphatase increased
11%
Nail discolouration
11%
Alanine aminotransferase increased
10%
Muscle spasms
10%
Pyrexia
10%
Abdominal pain upper
10%
Nail dystrophy
10%
Oropharyngeal pain
10%
Trichiasis
9%
Dyspnoea
9%
Vitamin D deficiency
9%
Onycholysis
9%
Cough
8%
Hyperbilirubinaemia
8%
Abdominal distension
8%
Hypokalaemia
8%
Hypertension
8%
Paronychia
8%
Onychoclasis
8%
Blood creatinine increased
8%
Aspartate aminotransferase increased
7%
Growth of eyelashes
7%
Fall
7%
Punctate keratitis
7%
Erythema
7%
Nasal congestion
7%
Platelet count decreased
6%
Conjunctivitis
6%
Lacrimation increased
6%
Nail disorder
6%
Nasopharyngitis
6%
Neuropathy peripheral
6%
Skin exfoliation
6%
Taste disorder
6%
Upper respiratory tract infection
6%
Cataract
6%
Eye pain
6%
Chills
6%
Blood bilirubin increased
6%
Depression
6%
Hyponatraemia
6%
Ocular hyperaemia
6%
Influenza like illness
5%
Dysphagia
5%
Vitreous floaters
5%
Cystitis
5%
Cholangitis
5%
Flank pain
5%
Hypotension
5%
Acute kidney injury
5%
Muscular weakness
5%
Neck pain
5%
Oral candidiasis
4%
Hyperuricaemia
4%
Weight increased
4%
Pain
4%
Ascites
4%
Skin fissures
4%
Lymphocyte count decreased
4%
Keratitis
3%
Breast pain
3%
Activated partial thromboplastin time prolonged
3%
Dyspnoea exertional
3%
Tinnitus
3%
Blood parathyroid hormone decreased
3%
Pollakiuria
3%
Bronchitis
3%
Cholangitis infective
3%
Non-cardiac chest pain
2%
Hypoalbuminaemia
2%
Rash maculo-papular
2%
Blood 1,25-dihydroxycholecalciferol increased
2%
Bacteraemia
2%
Failure to thrive
2%
Hypocalcaemia
2%
Sepsis
2%
Decubitus ulcer
2%
Pharyngitis
2%
Electrocardiogram QT prolonged
2%
Trichomegaly
2%
Palpitations
2%
Tachycardia
2%
Dysuria
2%
Hyperglycaemia
2%
Dysphonia
2%
Device occlusion
2%
Small intestinal obstruction
2%
Blood 1,25-dihydroxycholecalciferol decreased
2%
Chronic kidney disease
2%
Biliary obstruction
2%
Pleural effusion
2%
Pneumonia
2%
Hypercholesterolaemia
1%
Micturition urgency
1%
Biliary tract infection
1%
Enterobacter bacteraemia
1%
Hyperkalaemia
1%
Jaundice
1%
Kidney infection
1%
Oesophageal varices haemorrhage
1%
Retinal detachment
1%
Septic shock
1%
Skin infection
1%
Thrombosis
1%
Complication associated with device
1%
Intestinal obstruction
1%
Prostate cancer
1%
Seizure
1%
Pseudomonal bacteraemia
1%
Varices oesophageal
1%
Oral herpes
1%
Clostridium difficile infection
1%
Device leakage
1%
Gynaecomastia
1%
Somnolence
1%
Catheter site infection
1%
Gastrointestinal haemorrhage
1%
Haematemesis
1%
Hydronephrosis
1%
Optic ischaemic neuropathy
1%
Pneumonitis
1%
Transaminases increased
1%
C-reactive protein increased
1%
Cancer pain
1%
Candida infection
1%
Confusional state
1%
Herpes zoster
1%
Musculoskeletal pain
1%
Psoriasis
1%
Blood chloride decreased
1%
Cerebrovascular accident
1%
Malignant biliary obstruction
1%
Melaena
1%
Paraplegia
1%
Pneumonia aspiration
1%
Pneumonia pneumococcal
1%
Syncope
1%
Haemorrhoids
1%
Sinus pain
1%
Urinary tract pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort A: FGFR2 Rearrangements or Fusions
Cohort B: FGF/FGFR Alterations Other Than FGFR2 Rearrangements or Fusions
Cohort C: Negative for FGF/FGFR Alterations
Other
Total

FIGHT-210 Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort B: Non-squamous NSCLCExperimental Treatment1 Intervention
Participants with non-squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
Group II: Cohort A: Squamous NSCLCExperimental Treatment1 Intervention
Participants with squamous NSCLC with known or likely FGFR1-3 driver mutations outside the kinase domain or fusions/rearrangements will receive intermittent dosing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemigatinib
2022
Completed Phase 2
~220

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
364 Previous Clinical Trials
55,157 Total Patients Enrolled
Luisa Veronese, MDStudy DirectorIncyte Corporation
1 Previous Clinical Trials
83 Total Patients Enrolled

Media Library

Pemigatinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05253807 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: Cohort A: Squamous NSCLC, Cohort B: Non-squamous NSCLC
Non-Small Cell Lung Cancer Clinical Trial 2023: Pemigatinib Highlights & Side Effects. Trial Name: NCT05253807 — Phase 2
Pemigatinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05253807 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the enrolment capacity of this investigation?

"Affirmative. According to clinicaltrials.gov, the trial that began on April 29th 2022 is still open and currently seeking 125 individuals from 11 different sites."

Answered by AI

How likely is it that Pemigatinib may cause harm to patients?

"Our team at Power has evaluated Pemigatinib and assigned it a rating of 2 due to the existence of preliminary safety data from Phase 2 clinical trials, though efficacy remains unconfirmed."

Answered by AI

Are persons aged 70 or younger able to participate in this investigation?

"This clinical trial is open to any participant aged between 18 and 99. For those younger than 18, there are 49 trials available, while 2038 studies are suitable for persons over 65 years old."

Answered by AI

Am I eligible to enroll in this research project?

"This clinical trial seeks to enrol 125 participants, aged between 18 and 99, who have been diagnosed with carcinoma non-small-cell lung cancer. Patients must meet the following criteria: measurable disease according to RECIST v1.1; known/likely actionable FGFR alterations; progression after at least one prior therapy that is not likely to provide a benefit (or intolerant of or declining such therapy); an ECOG performance status of 0 - 2; baseline archival tumor specimen or willingness for biopsy before treatment; abstinence from pregnancy and fatherhood during study participation; confirmation of advanced/metastatic NSCLC based on AJ"

Answered by AI

What is the scope of the current research encompassing this trial in terms of hospitals?

"This medical study is being conducted in numerous research institutes and hospitals, including Florida Cancer Specialists & Research Institute (Saint Petersburg, FL), Florida Cancer Specialists (Lexington, KY) and University of Kentucky Hospital (Chicago, IL)."

Answered by AI

Is enrollment for this experimental research still open?

"Affirmative. Clinicaltrials.gov clearly states that the research has commenced enrollment, having been first published on April 29th 2022 and most recently updated on November 15th 2022. The investigators are hoping to recruit 125 participants from 11 different medical sites."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
2022. "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05253807.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top